After the brain surgery (missing data excluded), 80% of patients received whole-brain radiotherapy, 55%, chemotherapy, 20%, endocrine therapy, and 25% of HER2-positive patients based on primary tumor assessment received anti-HER2 therapy (trastuzumab, lapatinib, or sequentially both), including three patients who received lapatinib based on HER2 gain in the brain lesion. The gene discussed is ERBB2; the disease is neoplasm.